Misinterpretation of an inflammatory FDG uptake in a patient treated for Hodgkin lymphoma: a case report

Document Type : Case report

Authors

1 Nuclear Medicine Unit, University Hospital of Ferrara, Ferrara, Italy

2 Department of Translational Medicine, University of Ferrara, Ferrara, Italy

3 Hematology Unit, University Hospital of Ferrara, Ferrara, Italy

Abstract

Hodgkin Lymphoma (HL) is a malignancy involving lymph nodes and lymphatic system. [18F]F-FDG PET/CT (FDG-PET) imaging is routinely used for staging, to assess early chemotherapy response (interim FDG-PET), at the end of treatment (EoT FDG-PET) and for the identification of disease recurrence.
We present a case of a 39-year-old man treated for HL. FDG-PET scans performed after first line therapy (both Interim PET and at the end of therapy) demonstrated a persistent and significant mediastinal FDG uptake. The patient was treated with a second line therapy but the FDG-PET uptake did not change. After board discussion a new surgical, thoracoscopy-guided biopsy was performed. Histopathology demonstrated a dense fibrous tissue with occasional chronic inflammatory infiltrates.
Persistent FDG-PET positivity may suggest refractory or relapsed disease. However, occasionally, non-malignant conditions are responsible for a persistent FDG uptake, not related to primary disease. An accurate evaluation of clinical history and previous imaging exams is mandatory for clinicians and others experts to avoid misinterpretations of FDG-PET results. Nevertheless, in some cases, only a more invasive procedure, such as a biopsy, may finally lead to a definitive diagnosis.

Keywords

Main Subjects

References

  1. Gallamini A. Positron emission tomography scanning: A new paradigm for the management of Hodgkin’s lymphoma. Haematologica. 2010; 95(7):1046–8.
  2. Diehl V, Stein H, Hummel M, Zollinger R, Connors JM, Biol C. Hodgkin’s Lymphoma: Biology and Treatment Strategies for Primary, Refractory, and Relapsed Disease. Hematology. 2003; 225–47.
  3. Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Armand P, Bello CM, et al. Hodgkin lymphoma, version 2.2020. JNCCN J Natl Compr Cancer Netw. 2020; 18(6):755–81.
  4. Viamonte M, Johnson RE. Report of the Committee on Hodgkin’s disease Staging Cancer Res. 1994; 31(11): 1862–3.
  5. Panareo S, Urso L, Santi I, Rigolin GM, Cuneo A, Cittanti C, Bartolomei M. Right Atrium Mass Assessed with 18F-FDG PET/CT scan Turns Out to Be an Uncommon Relapse of Testicular Diffuse Large B-cell Lymphoma: A Case Report. Diagnostics. 2020; 10(11): 987.
  6. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: The lugano classification. J Clin Oncol. 2014; 32(27):3059–67.
  7. Gallamini A, Zwarthoed C, Borra A. Positron emission tomography (PET) in oncology. Cancers (Basel). 2014; 6(4):1821–89.
  8. Weber WA. Assessing tumor response to therapy. J Nucl Med. 2009; 50(SUPPL 1):1–10.
  9. Facey F, Bradbury I, Laking G, Payne E. Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers. Health Technol Assess (Rockv). 2007; 11(44).
  10. Eichenauer DA, Aleman BMP, André M, Federico M, Hutchings M, Illidge T, et al. Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018; 29: iv19–29.
  11. Dann EJ, Bairey O, Bar-Shalom R, Mashiach T, Barzilai E, Kornberg A, et al. Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients. Br J Haematol.2017; 178(5):709–18.
  12. Tabata MM, Novoa RA, Martires KJ. Paraneoplastic granulomatous dermatitis in a patient with Hodgkin’s disease: A diagnostic pitfall. BMJ Case Rep. 2018; 2018:bcr2018224961.
  13. Dubreuil J, Leenhardt J, Noel R, Salles G, Valette PJ, Skanjeti A. Sarcoidosis hepatoesplénica aislada: una trampa en la evaluacion del linfoma mediante 18F-FDG PET/TC. Rev Esp Med Nucl Imagen Mol. 2017; 36(6):399–400.
  14. Jerushalmi J, Frenkel A, Bar-Shalom R, Khoury J, Israel O. Physiologic thymic uptake of 18F-FDG in children and young adults: A PET/CT evaluation of incidence, patterns, and relationship to treatment. J Nucl Med. 2009; 50(6):849–53.
  15. Dubreuil J, Salles G, Bozzetto J, Tordo J, Djaïleb L, Berriolo-Riedinger A, et al. Usual and unusual pitfalls of 18F-FDG-PET/CT in lymphoma after treatment: A pictorial review. Nucl Med Commun. 2017; 38(7): 563–76.
  16. Zinzani PL, Tani M, Trisolini R, Fanti S, Stefoni V, Alifano M, et al. Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. Haematologica. 2007; 92(6):771-7.
  17. Borra A, Morbelli S, Zwarthoed C, Bianchi A, Bergesio F, Chauvie S, et al. Dual-point FDG-PET/CT for treatment response assessment in Hodgkin lymphoma, when an FDG-avid lesion persists after treatment. Am J Nucl Med Mol Imaging. 2019; 9(3):176–84.
  18. Minamimoto R, Fayad L, Advani R, Vose J, Macapinlac H, Meza J, et al. Diffuse large B-Cell lymphoma: Prospective multicenter comparison of early interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, deauville, and PERCIST criteria for early therapeutic monitoring. Radiology. 2016; 280(1):220–9.
  19. Mena E, Lindenberg ML, Turkbey BI, Shih J, Logan J, Adler S, et al. A pilot study of the value of 18F-fluoro-deoxy-thymidine PET/ CT in predicting viable lymphoma in residual 18F-FDG avid masses after completion of therapy. Clin Nucl Med. 2014; 39(10):874–81.
  20. Rahman HA, El Semary SF, Ahmed G, Kenaai N El, Omar W, Zaky I, et al. Can FDG-PET replace biopsy for the evaluation of residual tumor in pediatric mature B-cell non-Hodgkin lymphoma? Pediatr Blood Cancer. 2020; 67(9):1–5.
Asia Oceania Journal of Nuclear Medicine and Biology
Volume 11, Issue 2
July 2023
Pages 171-174

Files

Share

How to cite

Statistics